To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

National Institute on Drug Abuse (NIDA)8 enrolled

Overview

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.

Study Type

INTERVENTIONAL

Purpose

DIAGNOSTIC

Enrollment

Conditions

Amphetamine-Related Disorders

Interventions

LobelineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy individuals with a body mass index between 18 and 30. * Willing and able to give written consent. * Must have a negative drug test * Females must have a negative pregnancy test prior to study drug administration * Must have no medical contraindications as determined by routine testing Exclusion Criteria: * Please contact the site for more information

Locations (1)

U of CA, San Francisco

San Francisco, California, United States

Outcomes

Primary Outcomes

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.